Study summary · research use only
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review (species not specified; human clinical context) discusses diabetes mellitus (DM) and chronic kidney disease (CKD), summarizing trials of five drug classes: ACE inhibitors or angiotensin II receptor blockers, SGLT2 inhibitors, GLP-1 receptor agonists, type 1 endothelin receptor antagonists, and the mineralocorticoid receptor antagonist finerenone, describing reported effects including reduced albuminuria and proteinuria. It also lists novel agents in development for DM, obesity, or heart failure, including balcinrenone, baxdrostat, vicadrostat, tirzepatide, survodutide, retatrutide, cagrilintide, zibotentan, and avenciguat, describing them as intended to slow disease progression and reduce cardiovascular risk, and calls for integrated, patient-centered treatment approaches.
Abstract
Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (AIIRB); (2) sodium-glucose-transporter 2 (SGLT2) inhibitors; (3) glucagon-like peptide-1 receptor agonists (GLP-1 RA); and (4) an antagonist of type 1 endothelin receptor (ET1R) with proven efficacy to reduce albuminuria and proteinuria. (5) The mineralocorticoid receptor antagonist (MRA) finerenone has been tested in RCTs as a kidney protective agent. In our review, we summarize many of the principal trials that have generated evidence in this regard. Many novel agents-many of them proven not only for DM management but also for the treatment of obesity with or without DM or heart failure (HF)-are now in development and may be added to the five classical pillars: other non-steroidal MRA (balcinrenone); aldosterone synthase inhibitors (baxdrostat and vicadrostat); other GLP-1 RA (tirzepatide, survodutide, retatrutide, and cagrilintide); ET1 R antagonists, (zibotentan); and soluble guanylate cyclase activators (avenciguat). These new agents aim to slow disease progression further and reduce cardiovascular risk. Future strategies rely on integrated, patient-centered approaches and personalized therapy to curb renal disease and its related complications.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.